Abstract:

Pfizer’s business in China was established in 1980, and after 30 years of development, Pfizer China has become the largest multinational research-based biopharmaceutical company in China. The company has three pharmaceutical plants located in Suzhou, Dalian and Wuxi, and one management center in Beijing. It also set up two world-class R&D centers both located in Shanghai and Wuhan. Currently Pfizer China has more than 10,000 employees and more than 1 billion investment, and its business covers more than 200 cities all of China.

The business of Pfizer China is divided into two units: the bio-pharmaceutical business (WBB) and the diversified business (PDB). Moreover, the WBB contains six specific units, which are Primary Care 1 for high blood pressure and high cholesterol, Primary Care 2 for central nervous system, Anti-infective, Commercial and Diversified, Vaccines, and Oncology.  Major products include Lipitor, Norvasc, Viagra, Celebrex, Zithromax and so on.